QUIDELORTHO CORP Selling, General and Administrative Expense
QUIDELORTHO CORP (QDEL) reported Selling, General and Administrative Expense of $189.70 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-07
- QUIDELORTHO CORP selling, general and administrative expense for the quarter ending 2026-06-28 was $189.70M, a 6.57% increase year-over-year.
- QUIDELORTHO CORP selling, general and administrative expense for the quarter ending 2026-03-29 was $199.30M, a 6.58% increase year-over-year.
- QUIDELORTHO CORP selling, general and administrative expense for the quarter ending 2025-12-28 was $194.40M, a 3.68% increase year-over-year.
- QUIDELORTHO CORP selling, general and administrative expense for the quarter ending 2025-09-28 was $186.90M, a 0.27% increase year-over-year.
- QUIDELORTHO CORP selling, general and administrative expense for fiscal 2025 was $746.30M, a 2.67% decline from fiscal 2024.
- QUIDELORTHO CORP selling, general and administrative expense for fiscal 2024 was $766.80M, a 0.47% increase from fiscal 2023.
- QUIDELORTHO CORP selling, general and administrative expense for fiscal 2023 was $763.20M, a 22.90% increase from fiscal 2023.
- QUIDELORTHO CORP selling, general and administrative expense for fiscal 2023 was $621.00M, a 159.18% increase from fiscal 2022.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-28 | $189.70M 10-Q · filed 2026-08-07 | $389.00M 10-Q · filed 2026-08-07 | $583.40M derived: sum of 3 quarters · filed 2026-08-07 | $770.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-29 | $199.30M 10-Q · filed 2026-05-06 | $393.70M derived: sum of 2 quarters · filed 2026-05-06 | $580.60M derived: sum of 3 quarters · filed 2026-05-06 | $758.60M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-28 | $194.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $381.30M derived: sum of 2 quarters · filed 2026-02-19 | $559.30M derived: sum of 3 quarters · filed 2026-08-07 | $746.30M 10-K · filed 2026-02-19 |
| 2025-09-28 | $186.90M 10-Q · filed 2025-11-06 | $364.90M derived: sum of 2 quarters · filed 2026-08-07 | $551.90M 10-Q · filed 2025-11-06 | $739.40M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-29 | $178.00M 10-Q · filed 2026-08-07 | $365.00M 10-Q · filed 2026-08-07 | $552.50M derived: sum of 3 quarters · filed 2026-08-07 | $738.90M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-30 | $187.00M 10-Q · filed 2026-05-06 | $374.50M derived: sum of 2 quarters · filed 2026-05-06 | $560.90M derived: sum of 3 quarters · filed 2026-05-06 | $749.10M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-29 | $187.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $373.90M derived: sum of 2 quarters · filed 2026-02-19 | $562.10M derived: sum of 3 quarters · filed 2026-02-19 | $766.80M 10-K · filed 2026-02-19 |
| 2024-09-29 | $186.40M 10-Q · filed 2025-11-06 | $374.60M derived: sum of 2 quarters · filed 2025-11-06 | $579.30M 10-Q · filed 2025-11-06 | $766.90M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $188.20M 10-Q · filed 2025-08-06 | $392.90M 10-Q · filed 2025-08-06 | $580.50M derived: sum of 3 quarters · filed 2026-02-19 | $774.60M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $204.70M 10-Q · filed 2025-05-08 | $392.30M derived: sum of 2 quarters · filed 2026-02-19 | $586.40M derived: sum of 3 quarters · filed 2026-02-19 | $765.50M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $187.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $381.70M derived: sum of 2 quarters · filed 2026-02-19 | $560.80M derived: sum of 3 quarters · filed 2026-02-19 | $763.20M 10-K · filed 2026-02-19 |
| 2023-10-01 | $194.10M 10-Q · filed 2024-11-08 | $373.20M derived: sum of 2 quarters · filed 2024-11-08 | $575.60M 10-Q · filed 2024-11-08 | $789.20M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-07-02 | $179.10M 10-Q · filed 2024-08-01 | $381.50M 10-Q · filed 2024-08-01 | $595.10M derived: sum of 3 quarters · filed 2025-02-27 | $799.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-04-02 | $202.40M 10-Q · filed 2024-05-09 | $416.00M derived: sum of 2 quarters · filed 2025-02-27 | $620.20M derived: sum of 3 quarters · filed 2025-02-27 | $738.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-01-01 | $213.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $417.80M derived: sum of 2 quarters · filed 2025-02-27 | $536.20M derived: sum of 3 quarters · filed 2025-02-27 | $621.00M 10-K · filed 2025-02-27 |
| 2022-10-02 | $204.20M 10-Q · filed 2023-11-02 | $322.60M derived: sum of 2 quarters · filed 2023-11-02 | $407.40M 10-Q · filed 2023-11-02 | $481.10M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-07-03 | $118.40M 10-Q · filed 2023-08-09 | $203.20M 10-Q · filed 2023-08-09 | $276.90M derived: sum of 3 quarters · filed 2024-08-01 | $339.90M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-04-03 | $84.80M 10-Q · filed 2023-05-04 | $158.50M derived: sum of 2 quarters · filed 2024-08-01 | $221.50M derived: sum of 3 quarters · filed 2024-08-01 | $275.70M derived: sum of 4 quarters · filed 2024-08-01 |
| 2022-01-02 | $73.70M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-08-01 | $136.70M derived: sum of 2 quarters · filed 2024-08-01 | $190.90M derived: sum of 3 quarters · filed 2024-08-01 | $239.60M 10-K/A · filed 2024-08-01 |
| 2021-10-03 | $63.00M 10-Q · filed 2022-11-04 | $117.20M derived: sum of 2 quarters · filed 2022-11-04 | $165.90M 10-Q · filed 2022-11-04 | |
| 2021-07-04 | $54.20M 10-Q · filed 2022-08-05 | $102.90M 10-Q · filed 2022-08-05 | ||
| 2021-01-03 | $180.70M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |